NYSEAMERICAN:ZOM Zomedica (ZOM) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Zomedica Stock (NYSEAMERICAN:ZOM) Get Zomedica alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume790,936 shsAverage Volume4.72 million shsMarket Capitalization$95.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Zomedica Pharmaceuticals Corp. is a veterinary health company dedicated to improving the lives of companion animals through innovative diagnostic and therapeutic solutions. The company’s primary focus is on the development of point‐of‐care veterinary diagnostics and disease‐specific pharmaceuticals, aimed at empowering practitioners with timely information and treatment options for cats and dogs. Zomedica’s flagship offering is TRUFORMA, a bench‐top diagnostic platform designed to deliver rapid, accurate in‐clinic test results across a range of analytes including thyroid hormones, cortisol and infectious disease biomarkers. Beyond diagnostics, Zomedica is advancing its therapeutic pipeline with products targeting unmet needs in feline and canine health. Notably, the company is developing Palinveo, an oral treatment for hyperthyroidism in cats, currently progressing through regulatory review. By integrating diagnostics and targeted pharmaceuticals, Zomedica seeks to create a comprehensive “test‐and‐treat” ecosystem that enables veterinarians to diagnose and manage endocrine and metabolic disorders within a single practice setting. Founded in the early 2010s and headquartered in Ann Arbor, Michigan, Zomedica serves veterinary clinics across the United States and Canada, with plans to expand into additional international markets. Under the leadership of President and Chief Executive Officer Robert Cohen, the company has built strategic partnerships with veterinary distributors and academic research institutions to accelerate product development and market adoption. With a growing commercial footprint and a pipeline of novel products, Zomedica aims to become a leading provider of veterinary diagnostics and therapies for companion animal health.AI Generated. May Contain Errors. Read More Receive ZOM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zomedica and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZOM Stock News HeadlinesZomedica Corp. (ZOMDF) Q2 2026 Earnings Call TranscriptAugust 28, 2026 | seekingalpha.comZomedica Corp.: Zomedica Announces Strategic Collaboration with Boehringer Ingelheim Animal Health Canada Inc. to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA PlatformAugust 13, 2026 | finanznachrichten.deLabor Day Warning: The secret that called 1929 is flashing something newIn 1929, a young researcher named Irving Weiss spotted warning signs Wall Street ignored - then watched the Dow crash nearly 13% in a single day, followed by another 12% drop the next. His research became Weiss Ratings, a system The Wall Street Journal ranked number one for investment performance. It also called the Dot-Com Bust, the 2008 crisis, and the 2020 crash. Now the system is flagging a possible shift in the back half of 2026, separating stocks it flags as vulnerable from those positioned to climb.September 4 at 1:00 AM | Weiss Ratings (Ad)ZOMEDICA CORPJuly 30, 2026 | finanznachrichten.deZomedica Corp. (ZOMDF) Discusses Sales Strategy and Execution in Veterinary Medicine TranscriptJuly 25, 2026 | seekingalpha.comZomedica Corp.: Zomedica Announces "Fourth Friday at Four" Webinar on July 24, 2026: Zomedica's Sales Organization - From Strategy to the ClinicJuly 15, 2026 | finanznachrichten.deZomedica Corp. (ZOMDF) Discusses Five Pillars Framework for Clinical Value and Shareholder Returns in Veterinary Practice TranscriptJune 26, 2026 | seekingalpha.comZomedica Corp. (ZOMDF) Q1 2026 Earnings Call TranscriptMay 29, 2026 | seekingalpha.comSee More Headlines ZOM Stock Analysis - Frequently Asked Questions How were Zomedica's earnings last quarter? Zomedica Corp. (NYSEAMERICAN:ZOM) issued its quarterly earnings results on Thursday, November, 7th. The company reported ($0.01) EPS for the quarter. The company earned $7 million during the quarter. Zomedica had a negative trailing twelve-month return on equity of 12.47% and a negative net margin of 232.88%. Read the conference call transcript. How do I buy shares of Zomedica? Shares of ZOM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Zomedica own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zomedica investors own include Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NIO (NIO), Bakkt (BKKT), Phunware (PHUN) and Company Calendar Last Earnings11/07/2024Today9/04/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSEAMERICAN:ZOM CIK1684144 Webwww.zomedica.com Phone734-369-2555FaxN/AEmployees50Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$34.53 million Net Margins-232.88% Pretax Margin-232.24% Return on Equity-12.47% Return on Assets-11.84% Debt Debt-to-Equity RatioN/A Current Ratio10.82 Quick Ratio10.15 Sales & Book Value Annual Sales$25.19 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.24 per share Price / BookN/AMiscellaneous Outstanding Shares979,950,000Free Float938,890,000Market Cap$95.35 million OptionableNot Optionable Beta1.03 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NYSEAMERICAN:ZOM) was last updated on 9/4/2026 by MarketBeat.com Staff. From Our PartnersThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredBefore Anthropic becomes impossible to ignore...Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...The Oxford Club | SponsoredThey're not buying gold. They're buying this.Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredAfter KDA, PRE, and OCEAN—this is the one17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...Crypto 101 Media | SponsoredWall Street pays $32K for this type of stock market data. (But see this Labor Day deal now!)The Bloomberg Terminal costs $32,000 a year and sits on the desks of more than 350,000 Wall Street traders. Mo...Weiss Ratings | SponsoredThis Overlooked Fund Turns AI Stocks Into Weekly IncomeA small fund pays investors weekly income from AI stocks that don't pay dividends on their own. Chief Incom...Investors Alley | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zomedica Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zomedica With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
